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Despite the prevalence of methamphetamine (meth) use disorder, research on meth is 
disproportionately scarce compared to research on other illicit drugs. Existing evidence 
highlights cognitive deficits as an impediment against daily function and treatment of 
chronic meth use. Similar deficits are also observed in schizophrenia, and this review 
therefore draws on schizophrenia research by examining similarities and differences 
between the two disorders on cognition and related neural findings. While meth use 
disorder and schizophrenia are two distinct disorders, they are highly co-morbid and 
share impairments in similar cognitive domains and altered brain structure/function. This 
narrative review specifically identifies overlapping features such as deficits in learning and 
memory, social cognition, working memory and inhibitory/impulse control. We report 
that while working memory deficits are a core feature of schizophrenia, such deficits 
are inconsistently observed following chronic meth use. Similar structural and functional 
abnormalities are also observed in cortical and limbic regions between the two disorders, 
except for cingulate activity where differences are observed. There is growing evidence 
that targeting cognitive symptoms may improve functional outcome in schizophrenia, 
with evidence of normalized abnormal brain activity in regions associated with cognition. 
Considering the overlap between meth use disorder and schizophrenia, targeting cognitive 
symptoms in people with meth use disorder may also improve treatment outcome and 
daily function.
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INTRODUCTION
Methamphetamine (meth) use disorder is defined by the 
Diagnostic and Statistical Manual of Mental Disorders 5th 
edition (DSM-5) as a substance use disorder characterized by 
compulsive meth-taking and -seeking despite serious negative 
consequences (1). Amphetamines are the second most used illicit 
drug in the world, second only to cannabis (2). Meth represents 
the majority of illicitly used amphetamines and is an urgent global 
health threat, with a rapidly increasing market (3). The Substance 
Abuse and Mental Health Services Administration estimated that 
close to 13 million people in the United States used meth in their 
lifetime (~4% of the total population), with 569,000 people using 
meth in the past month (4). There is no government-approved 
medication to treat meth use disorder, and existing psychological 
interventions need much improvement in efficacy (5).
Despite the prevalence and associated harm, PubMed 
indicates that research on meth is disproportionately low 
compared to other substance use disorders (6) and other mental 
disorders. We thus propose to harness existing research in 
schizophrenia to provide much needed insight into meth use 
disorder to improve and innovate its therapeutics considering 
the evidence for their shared psychotic symptoms and genetic 
vulnerability (7–9). Schizophrenia is a chronic neuropsychiatric 
disorder characterized by disturbances in thought, perception, 
and behavior (1), and it is an extensively researched field with 
PubMed publications per year almost doubling all of illicit 
substance publications per year and more than ten times the 
number of publications on meth (Figure 1). Other than its wealth 
of existing data, schizophrenia is one of the best fields to leverage 
to understand meth use disorder because it is highly co-morbid 
with meth use (10). Meth is amongst the most used illicit substance 
in people with schizophrenia (11). Importantly, chronic meth 
use might promote the development of schizophrenia in at-risk 
individuals (12, 13), and a major animal model to capture some 
of schizophrenia-like psychotic symptoms relies on chronic meth 
exposure (14). For example, impairment in prepulse inhibition, 
a measurement of sensorimotor gating deficits often observed in 
people with schizophrenia (15), can be elicited following chronic 
meth exposure in rodents (16–19). To the best of our knowledge, 
no study has assessed sensorimotor gating impairment in people 
with meth use disorder, but rodent evidence suggests that 
chronic meth exposure in early life and adolescence may lead to 
long-lasting deficits in prepulse inhibition in adulthood in mice 
(20, 21).
Taken together, cognitive deficits and their associated neural 
dysfunction characterize both disorders (22–29). However, 
they have never been explicitly compared. The shared cognitive 
deficits are important to understand considering that many 
schizophrenia patients use psychostimulants as self-medication 
to reduce positive and negative symptoms, and improve mood 
states (30). Such efforts in turn may potentiate or exacerbate 
cognitive symptoms. Also, cognitive deficits are associated 
with poorer functional outcome in both disorders (31–33), 
hence existing effective therapies targeting cognitive deficits in 
schizophrenia may provide treatment avenues for similar deficits 
in meth use disorder.
The aim of this review is first to compare and contrast the 
cognitive impairments and related brain structure/activity 
between meth use disorder and schizophrenia. While many of the 
impairments are similar between the two, the associated neural 
changes can be different, which is important to understand the 
potential nuances in shared factors between the two disorders. We 
will then discuss approaches to treat cognitive symptoms in both 
disorders, with a focus on cognitive remediation therapy (CRT). 
The current review exclusively discusses studies in people with a 
DSM-IV or DSM-5 diagnosis of meth use disorder/dependence 
rather than to broadly include studies examining acute or casual 
meth users. This is to limit the substantial variability observed in 
findings due to large differences in meth intake between casual vs 
dependent users. Acute meth use and associated meth-induced 
psychosis-related cognitive deficits will not be discussed. Notably, 
there are limited studies that have directly compared people 
with meth use disorder and schizophrenia. We thus examined 
characteristics that were explicitly investigated in people with 
meth use disorder (Table 1) and then compared them against 
independent findings on schizophrenia. Where possible, studies 
that have directly compared the two disorders were highlighted.
COGNITIve DeFICITS AND ReLATeD 
BRAIN DYSFUNCTION
Meth specifically acts on dopamine release by disrupting 
intravesicular pH and reversing transport of dopamine via 
plasma membrane transporters, which impairs the uptake of 
dopamine and its concentration within synaptic vesicles. The 
result is higher cytosolic concentrations of dopamine in nerve 
terminals, which leads to excess dopamine concentration in the 
synaptic cleft (71–73). This likely leads to lasting neuroadaptations 
(74) to affect cognition. Subcortical hyperdopaminergia and 
prefrontal hypodopaminergia is hypothesized to be part of the 
FIGURe 1 | The number of PubMed publications in the last 50 years on 
schizophrenia or methamphetamine.












TABLe 1 | Summary of studies that have investigated cognitive deficits in meth use disorder, ordered in ascending order of shortest abstinence length reported in the sample. Percentage of female participant is 
specified if reported.
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ANT, attention networks task; AVLT, auditory verbal learning test; BIS, Barratt impulsiveness scale; BVMT-R, brief visuospatial memory test—revised; CFT, complex figure test; CPAL, continuous paired association 
learning task; CPT, continuous performance test; CVLT, California verbal learning test; DDT, delayed discounting task; DNM, delayed non-match to sample task; DMS, delayed match to sample; HVLT-R, Hopkins 
verbal learning test—revisited; ISL, international shopping list task; LNS, letter-number sequence; MIST, memory for intentions screening test; OCL, one card learning task; PASAT, paced auditory serial addition task; 
RBANS; repeatable battery for the assessment of neuropsychological status; SCAP, spatial capacity delayed response test; SSRT; stop-signal reaction time; SWM, spatial working memory span; VMS, visual memory 
span; WCST, Wisconsin card sorting test; WMS, Wechsler memory scale.
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pathophysiology of schizophrenia (75), which may cause neural 
dysfunction associated with cognition overlapping with chronic 
meth use. A meta-analysis reported that people with meth use 
disorder show deficits of medium effect size in cognition (76). 
In people with schizophrenia, impairments of medium to large 
effect sizes are observed in similar domains (77).
The scope and breadth of cognition studies in meth use 
disorder are severely lacking compared to schizophrenia. 
Thus, the present review specifically highlights dominantly 
studied aspects of cognition in chronic meth use, namely 
learning and memory, social cognition, and two key executive 
functions: working memory and inhibitory/impulsive control. 
The findings are then compared against corresponding studies 
in schizophrenia.
Learning and Memory
While all types of memory are not yet assessed in meth use 
disorder, there is strong evidence that both current and abstinent 
meth users display mild impairments in visual, verbal, and 
prospective learning and memory (22, 32, 39–41, 43–47, 54, 
58–63, 67, 70), even observed after 1.8 years of abstinence 
(Table 1). People with schizophrenia display severe impairments 
in similar domains examined using the same tests (78–80). 
Prospective memory impairments are of particular interest 
because they are negatively associated with treatment outcomes 
due to poorer adherence to medication regimens (81) and greater 
likelihood of missed appointments (79).
While it is difficult to establish meth dependence in animals, 
preclinical rodent studies using chronic meth exposure 
(minimum 7 days of exposure) suggest a long-lasting causative 
effect of meth on different types of learning and memory. 
Meth self-administrating rats display both short- and long-term 
impairments in recognition memory (82, 83). In contrast, 
experimenter-led chronic injections of meth only impairs 
long-term recognition memory (84). In a study investigating 
the effect of meth on auditory associative learning and memory, 
experimenter-led chronic injections of meth disrupted recall of 
inhibitory memory, whereas meth self-administration disrupted 
associative learning (85). Spatial memory impairments are 
also observed in self-administrating rats and rats subject to 
experimenter-led chronic injections (86–88), with effects lasting 
up to 3 weeks following abstinence (89). In contrast, a study by 
Kesby and colleagues (90) found that experimenter-led chronic 
meth injections may improve learning in mice in a visual 
discrimination task (90). Taken together, it may be that chronic 
meth injections may initially improve learning processes but lead 
to deficits in the long-term, whereas meth self-administration 
consistently lead to memory impairments.
Learning and memory processes rely on the prefrontal cortex 
(PFC) and medial temporal lobe including the hippocampus 
(91). Altered structure and activity of these regions have been 
described in both meth use disorder and schizophrenia that may 
be associated with poorer memory. For example, a MRI study 
showed an association between decreased bilateral hippocampal 
volume and poorer performance on a word-recall task in 
current meth users (22), although a recent study with bigger 
sample size failed to find a link between visual/verbal memory 
and hippocampal volume in abstinent meth dependents (92). 
In schizophrenia, the association between decreased bilateral 
hippocampal volume and poorer performance on a verbal recall 
task is well established (93). This suggests a shared role for 
hippocampal volume reduction in verbal learning and memory 
impairments in both disorders.
No study has investigated the neural correlates of prospective 
memory performance in people with meth use disorder, but 
there is one study in people with schizophrenia. Chen et al. 
(29) found that compared to healthy controls, people with 
schizophrenia displayed hypoactivity in the frontal, parietal and 
temporal cortex (29). Indeed, prospective memory performance 
and activation of the rostral PFC and parietal lobe are positively 
associated in healthy people (94). People with meth use disorder 
or schizophrenia display reduced gray matter in the parietal lobe 
(35, 95, 96,), which may explain the visual learning and memory 
deficits observed. In addition, parietal gray matter reduction is 
observed in people with childhood-onset schizophrenia (95) 
and adolescents with meth use disorder (35). These findings 
suggest a role for parietal lobe that may be an early-onset risk 
factor for both disorders that may be targeted for treatment in 
childhood/adolescence.
Social Cognition
A recent meta-analysis in people with meth use disorder found 
that social cognition impairments were amongst the largest 
cognitive deficits observed, specifically in theory of mind (ToM) 
and emotion processing (76), which are also widely described in 
schizophrenia (97, 98). There is mice evidence suggesting a link 
between chronic meth injections during mid-late adolescence 
and disruption of social interaction following 2 weeks of 
abstinence in males (99). While social cognition deficits are 
apparent in current and short-term abstinent meth dependents 
(32, 50, 51), there is conflicting evidence following long-term 
abstinence. For example, Henry et al. (59) found impairments 
of large effect size in participants with meth use disorder who 
have been abstinent for 3-8 months compared to healthy controls 
(59), whereas Zhong et al. (32) observed no differences after 7.5 
months of abstinence (32). Given that social cognition deficits 
have a significant negative impact on social and vocational 
functioning in people with schizophrenia (100, 101), it is clear 
that further research of the deficit and its functional implications 
is warranted in people with meth use disorder.
Key brain structures underlying social cognition include 
ventro- and dorsolateral PFC (vlPFC and dlPFC), orbitofrontal 
cortex, anterior cingulate cortex (ACC), insular cortex, and 
amygdala (102–104). Indeed, alterations in those regions 
underlying social cognition are observed in meth use disorder 
and schizophrenia. Compared to healthy controls, there is 
reduced activation of the vlPFC and dlPFC in meth dependents 
(105, 106) and people with schizophrenia (107, 108) in response 
to threatening or fearful faces. Such prefrontal dysfunction 
may indicate failure to integrate socio-emotional information 
(109). People with schizophrenia also display hypoactivity 
of the cingulate cortex in response to negative words (107). 
In contrast, hyperactivity of the ACC and posterior cingulate 
cortex (PCC) is associated with response to negative emotions 
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in people with meth use disorder (105, 106). Considering that 
ACC hyperactivity is linked to hypersensitivity to threat (106) 
and PCC hyperactivity is linked with recollection of past negative 
memories (105), it may be that emotional processing deficits 
arises from hyposensitivity to threat/sadness in schizophrenia 
but hypervigilance/distraction to threat/sadness in meth use 
disorder. This has important treatment implications and should 
be investigated.
Bilateral insular hypoactivity is observed in people with meth 
use disorder when presented with fearful and threatening images 
(105). Similarly in schizophrenia, left insular hypoactivity is 
associated with happy and fearful facial expression processing 
(110, 111), and disgust facial expressions in non-paranoid 
people with schizophrenia (112). Left insular hypoactivity when 
presented with sad faces is associated with adolescent-onset 
schizophrenia (113), which suggests that insular hypoactivity 
to sad faces may also be involved in adolescent-onset meth use. 
Consistent with functional MRI (fMRI) findings, insular cortex 
gray matter volume reduction is also observed in people with 
meth use disorder (24, 114, 115) or schizophrenia (95, 116). In 
fact, a meta-analysis revealed that insular gray matter showed the 
largest decrease of all brain regions in people with schizophrenia 
(96), with larger volume reduction in the anterior compared to 
the posterior insular cortex (117). Such insular abnormalities 
in both disorders may be linked to decreased empathy and 
abnormal response to threatening situations (105).
While a recent neuroimaging meta-analysis revealed large 
decreases in insular and bilateral medial PFC activation 
during ToM tasks in people with schizophrenia (118), 
no studies have investigated the neural correlate of ToM 
impairments in people with meth use disorder. ToM deficits 
appear consistent in meth use disorder, thus it would be 
interesting to examine whether its neural correlates are 
shared with people with schizophrenia.
executive Functions: working Memory 
and Inhibitory Control
Executive functions are high-order cognitive processes 
necessary to balance new ideas, think before acting, remain 
focused, and resist temptations to ultimately control behaviors 
such as decision making (119). Such cognitive processes 
include inhibitory control, working memory, attentional 
control, and cognitive flexibility. Moderate to severe 
impairments in working memory and inhibitory control 
have been described in meth use disorder and schizophrenia 
(76, 120–123). Longitudinal evidence suggests that executive 
function impairments may predispose individuals to 
developing schizophrenia (124). While there is no such study 
in people with meth use disorder, a rodent study showed 
that reduced executive function leads to increased meth self-
administration (125), suggesting that individual differences 
in executive function may contribute to the development 
and maintenance of meth dependence. This review will focus 
working memory and inhibitory control because other types 
of executive function have not been as thoroughly assessed in 
people diagnosed with meth use disorder.
Working Memory
Some studies have reported an association between working 
memory impairments and meth dependence in both current (40, 
41, 53) and abstinent (32, 43, 48, 58, 62, 63, 66) chronic meth users, 
whereas others have found no association (44, 45, 49, 60, 64, 67). 
Although this may be due to different periods of abstinence across 
studies, inconsistent findings are still observed across studies 
with similar length of abstinence (Table 1). Additionally, some of 
the strongest effects of meth use on working memory were found 
in polydrug users (53, 63). Nevertheless, a meta-analysis recently 
revealed a moderate overall deficit in working memory in meth 
use disorder (76). In addition, male rats receiving chronic meth 
injections show long-lasting impairments in spatial working 
memory (126, 127). Given that impaired working memory in 
meth users is associated with disrupted social adaptation, global 
functioning, and unemployment (31, 32), more research is 
needed to elucidate whether such deficits are a predictor for the 
development of meth use disorder or a consequence of chronic 
meth use. In schizophrenia, working memory deficits form a 
core feature (120, 121), and premorbid working memory may be 
one of the most prominent factors predisposing individuals to 
developing the disorder (124, 128).
Studies focusing on working memory processes observed 
both hyper- and hypoactivation of the dlPFC in people with 
schizophrenia (27). Discrepancies between studies may to be 
due to varying task difficulty across studies (27), suggesting 
an association between dlPFC activation and degree of 
working memory impairments. We are not aware of an fMRI 
investigation during working memory tasks in people with meth 
use disorder. However, a perfusion MRI study found a positive 
correlation between working memory performance and regional 
cerebral flow in the left temporoparietal region and in the right 
lateral parietal cortex of abstinent meth users (64). Given that 
not all people with meth use disorder display impairments 
in working memory (Table 1), it would be informative to 
investigate individual patterns of frontal lobe dysfunction 
associated with such deficits and investigate whether a hyper- or 
hypoactivity emerges.
Inhibitory Control
The Stroop task, which measures the ability to suppress 
irrelevant information, is one of the most commonly used tests 
of inhibitory control in neuropsychiatric patients. Chronic meth 
use is associated with poorer performance in the Stroop task in 
adolescents (35, 37, 65) and adults with meth use disorder (23, 26, 
34, 40, 41, 45, 66–52). Effects in adolescents suggest that reduced 
inhibitory control may be a predisposing factor to developing 
meth use disorder. There is extensive evidence that schizophrenia 
also leads to poorer performance on the Stroop task compared 
to controls (122, 123). Salo et al. (2011) explicitly compared 
Stroop performance between people with schizophrenia and 
people with meth use disorder, and found greater inhibitory 
deficits in early abstinent (2–7 days) meth dependents compared 
to schizophrenia patients (52). This suggests that withdrawal 
from meth may contribute to the severity of cognitive symptoms 
because the inhibition deficits and withdrawal symptoms 
decreased over time (52). Inhibitory control and impulsivity are 
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associated (129). Indeed, people with schizophrenia or meth 
use disorder both display poor impulse control (24, 25, 36, 38, 
42, 130, 131). Notably, impulse-related functions are among the 
most impaired in meth use disorder (76), and poor impulsivity is 
regarded as one key predisposing factor to developing substance 
use disorder (132). In addition, Monterroso et al. (42) found that 
reaction time in an impulse control task positively correlates 
with grams of meth used per week, highlighting the relationship 
between poor impulse control performance and the extent 
of recent meth use (42). These deficits have important clinical 
implications. In meth use disorder, impaired inhibition is linked 
with unemployment (31), and poor impulse control is associated 
with treatment non-completion (133) and relapse (134). In 
schizophrenia, poorer inhibition and greater impulsivity have 
a negative impact on daily function (135, 136). In rodents, 
chronic meth injections lead to an age-dependent impairment 
in inhibition (78, 130). Interestingly, this effect is not observed 
after a week of withdrawal (131), suggesting that abstinence may 
reverse deficits in inhibition.
Inhibitory control impairments correlate with reduced gray 
matter volume in the middle frontal gyrus in meth use disorder 
(57). In schizophrenia, a reduction in orbital inferior frontal gray 
matter is observed (137). Disrupted frontal white matter integrity 
is linked with impulsivity (25) and inhibition (35) in meth use 
disorder. Meth dependents also display structural abnormalities 
in the genu of the corpus callosum (138, 139), a white matter 
tract which carries fibers originating from the PFC. Poorer 
corpus callosum integrity is associated with impaired inhibition 
(140, 141) and impulse control (38). In addition to structural 
abnormalities, people with meth use disorder display reduced 
activation of the PFC when performing the Stroop task (56), more 
specifically in the right inferior frontal gyrus (IFG), ACC (23) 
and the PFC (26). Likewise, people with schizophrenia display 
hypoactivity of the right IFG, ACC, and PFC when performing 
similar tasks (28, 142). Hypoactivity in the ACC and right IFG is 
also observed in people with early onset schizophrenia (143). It 
would be important to also examine these brain regions during 
executive function tasks in people with adolescent- vs adult-
onset of meth use disorder.
Metabolic alteration of the ACC is also associated with 
impaired inhibitory control in both disorders, which is measured 
by levels of N-acetylaspartate, a marker of neuronal integrity 
(144). Reduced N-acetylaspartate levels in the ACC are observed 
in meth use disorder (145) and schizophrenia (146–149). 
N-acetylaspartate levels correlate with poorer attention and 
inhibition in adult (68) and adolescent (37) meth users, and 
people with schizophrenia (150–152). Interestingly, reduced 
N-acetylaspartate in ACC is more dramatic with early onset of 
meth use (37), and reduced ACC levels of N-acetylaspartate are 
present at the early stages of schizophrenia (149), and in high-
risk offspring of schizophrenia patients (152).
Taken together, impairments in learning and memory, 
social cognition, working memory and inhibitory control are 
observed in schizophrenia and meth use disorder. Such deficits 
affect treatment completion and outcomes in both conditions 
(31, 32, 79, 81, 100, 135, 136). While there is evidence that 
cognitive deficits may be a risk factor for the development of 
schizophrenia, it remains unclear whether they predispose an 
individual towards meth dependence or are the result of chronic 
meth use. Brain studies suggest that people with schizophrenia 
and meth use disorder display largely similar patterns of 
structural and functional brain abnormalities in regions involved 
in key cognitive processes, with the exception of brain regions 
underlying emotion regulation (Figure 2). Such abnormalities 
may predict disease progression. What is clear from all the 
existing studies of cognition and related brain regions in meth use 
disorder is how much the findings overlap with corresponding 
studies in schizophrenia, with far more similarities compared 
to differences between the two disorders. This is in contrast to 
the many symptomatic differences between the two disorders 
(7, 153). While we do not know the mechanisms underlying 
such similarities in cognitive deficits and brain dysfunction, 
such overlaps provide an important opportunity to consider 
employing existing schizophrenia therapies for people with meth 
use disorder.
INTeRveNTIONS TO IMPROve 
COGNITION IN MeTH USe DISORDeR: 
INSIGHTS FROM SCHIZOPHReNIA 
ReSeARCH
The use of various pharmacotherapies to improve cognition in 
people with schizophrenia have yielded mixed results. A meta-
analysis revealed that medication targeting the cholinergic 
system result in marginal improvement in verbal and spatial 
learning and memory (154). Preliminary evidence also suggest 
that oxytocin may improve social cognition and verbal learning 
and memory (155), but the efficacy of such intervention has 
proven to be inconclusive and more research is still needed (101). 
Results from a large scale multisite study suggests that treatment 
with antipsychotic medication only results in limited cognitive 
improvement (156). In addition to pharmacological treatments, 
a recent systematic review found that repeated transcranial 
magnetic stimulation may be beneficial in improving verbal 
and working memory, but not other functions such as cognitive 
flexibility (157).
On the other hand, CRT has shown promising results in 
the alleviation of cognitive deficits, with several meta-analyses 
revealing improvement of medium effect sizes in people with 
schizophrenia (158, 159). The Cognitive Remediation Experts 
Workshop (Florence, Italy, 2010) defines CRT as a “behavioral 
training-based intervention that aims to improve cognitive 
processes with the goal of durability and generalization”. A 
range of CRTs have been developed over the past 50 years to 
target cognitive symptoms specifically in schizophrenia, with 
CRT well received by participants (160, 161). CRTs use diverse 
methods, such as drill and practice exercises, cognitive strategies 
training, and group discussions (159, 162). Consistent with the 
present review’s observations that cognitive deficits overlap in 
schizophrenia and meth use disorder, preliminary evidence 
suggests that CRTs are also beneficial in people with meth use 
disorder (163, 164). Especially exciting are the results of two meta-
analyses in schizophrenia patients that revealed CRT increased 
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FIGURe 2 | Summary of the neurobiology underlying cognitive impairments in meth use disorder and schizophrenia. (A) People with meth use disorder or 
schizophrenia display similar patterns of gray matter reduction associated with learning and memory impairments in the hippocampus (HPC) and parietal lobe. 
People with schizophrenia also display reduced activity in the frontal, parietal and temporal lobes. (B) People with meth use disorder or schizophrenia display 
similar patterns of gray matter reduction associated with social cognition impairments in the insular cortex. They also display reduced activity in the dorsolateral and 
ventrolateral prefrontal cortices (dlPFC and vlPFC, respectively). They display opposite patterns of activity in the anterior and posterior cingulate cortices (ACC and 
PCC, respectively). (C) People with meth use disorder or schizophrenia display similar reduced activity in the vlPFC, ACC and inferior frontal gyrus (IFG) associated 
with executive dysfunction. People with schizophrenia may display dlPFC hypo- or hyperactivity, depending on task difficulty and working memory load. Executive 
dysfunction is also associated with reduced medial frontal gyrus (MFG) gray matter in people with meth use disorder, and reduced orbital IFG gray matter in people 
with schizophrenia.
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activation of brain regions affected in meth use disorder such 
as the dlPFC, mPFC, parietal cortex, insula, and thalamus (165, 
166), and increased white matter integrity of the corpus callosum 
was also observed (167), highlighting that CRT may address 
the neurobiology underlying cognitive impairments. Overall, 
CRT has been shown to more consistently improve cognition 
in people with schizophrenia compared to other therapeutics 
avenues, with effect sizes varying between domains. CRT will 
therefore be the focus of this review.
Targeting Learning and Memory Deficits
Improvements in verbal memory are observed in people with 
schizophrenia following CRT (158, 159). There is also evidence 
that cognitive training may improve event-based prospective 
memory in people with schizophrenia (80). Although prospective 
memory training appears to be a promising treatment approach, 
effect on daily function and functional outcome has yet to be 
investigated in schizophrenia.
To the best of our knowledge, similar memory training in 
people with meth use disorder has not yet been described. Given 
the negative impact of poor prospective memory on treatment 
outcome, it would be beneficial to consider developing CRT 
targeting such deficits in meth use disorders. CRT focusing 
on verbal and prospective memory training may be the most 
effective to treat meth use disorder because visual learning and 
memory is one of the few cognitive domains failing to respond to 
CRT (158, 159). Considering the overlapping link between verbal 
memory and hippocampal volume, frontal and parietal lobe 
function in both disorders, it would be informative to investigate 
whether CRT affects structure and function of those regions.
Targeting Social Cognition Deficits
Bechi and colleagues (168) showed that combination of CRT 
and social cognitive or ToM training improved social cognitive 
abilities even further than CRT alone in people with schizophrenia 
(168). ToM training involves reading comic strips to be trained 
to recognize relevant details and collect and meaningful pieces of 
information such as place, time, characters’ actions, and physical 
features. Another study revealed that adding to standard CRT 
computerized social cognition training such as the interactive 
guide to emotions that is designed to train patients to recognize 
emotions and other mental states, produced greater improvement 
not only in social cognition, but also other cognitive domains 
such as visual memory and executive function in people with 
schizophrenia (169). Evidence reviewed by Campos et al. (170) 
revealed that emotion recognition training leads to an increase 
in activation in the fronto-temporal-occipital regions, postcentral 
gyrus, right amygdala, medial PFC, and right putamen in 
people with schizophrenia (170). Hyperactivity in those regions 
correlated with social cognition improvement, in particular medial 
PFC activation was associated with increased social functioning 
6 months after treatment (170). Such evidence in schizophrenia 
suggests emotion recognition training as a strong candidate 
to improve social cognition in people with meth use disorder. 
However, interventions specifically targeting social cognition have 
not yet been studied in people with meth use disorder. Note that 
there is an opposite pattern of cingulate dysfunction underlying 
emotion regulation observed in people with schizophrenia and 
meth use disorder (Figure 2). It is possible that there is a dissociation 
between the two disorders in how emotion recognition training 
affects the cognitive deficits and the related hyperactivity in the 
cingulate cortex.
Targeting working Memory Deficits
Evidence reviewed by Lett et al. (171) suggests that computer-
based programs using auditory exercises aiming to improve 
the speed and accuracy of auditory information processing 
produce long-lasting improvement in verbal working memory 
in people with schizophrenia (171). This is in line with a recent 
meta-analysis specifically investigating computer-based drill and 
practice training (172). Prikken et al. (172) found that working 
memory was among the most improved domains, and noted that 
shorter, but more intense training programs yielded larger effect 
sizes (172). On the other hand, they found limited improvements 
in functional outcome (172), which suggests that computerized 
training programs should be used in conjunction with another 
line of CRT involving face-to-face training.
Consistent with schizophrenia research, a pilot study in 
people with meth use disorder found improvement in working 
memory following four weeks of increasingly difficult N-back 
memory task training, which was also linked to improved 
impulse control (164). In people with meth use disorder, it is 
promising that working memory training has been shown to 
normalize frontostriatal structure and function (163).
SUMMARY
Meth use disorder and schizophrenia are two distinct but often 
comorbid mental disorders. The present review highlights 
shared cognitive impairments and brain abnormalities in 
people with schizophrenia or meth use disorder, with the 
hope to gain insight from schizophrenia research to develop 
treatments for people with meth use disorder, which is a global 
problem with increasing health, social and economic burden 
(173). Their shared key features including deficits in learning, 
memory, social cognition, working memory and inhibitory 
control, and abnormal frontostriatal and insular cortex 
structure and function, all impact on treatment outcome and 
daily functioning. There is some evidence that these deficits and 
abnormalities may precede the development of the disorders. 
Targeted treatment of the cognitive deficits in a vulnerable 
population may improve brain and cognition, and prevent or 
delay the onset of the disorders. Such treatment approaches 
for meth use disorder can capitalize on the well-established 
literature on schizophrenia. Specifically CRTs have been shown 
to successfully improve cognitive impairments, normalize 
brain function, and increase treatment efficacy in people with 
schizophrenia, and these treatment approaches should be 
examined for their efficacy to improve similar impairments 
in people with meth use disorder. This is an urgent call to 
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action because there is no FDA-approved pharmacotherapy 
to treat stimulant use disorders. Importantly, more research is 
needed to fully understand the mechanisms underlying CRT, 
with the aim to tailor CRT for each individual patient with 
different levels of cognitive and brain impairments that have 
been shown to affect treatment outcomes.
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